NBIX
Neurocrine Biosciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$155.64
−1.71%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
18.4x
EV/EBITDA
17.2x
Market Cap
$15.82B
MomentumView details →
1D Return
−1.71%
YTD Return
+10.21%
RSI (14)
45.1
ValuationView details →
P/E (Fwd)
18.4x
EV/EBITDA
17.2x
Market Cap
$15.82B
RSI (14)
45.1
MomentumView details →
1D Return
−1.71%
YTD Return
+10.21%
SummaryUpdated Jun 1, 2026
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a San Diego-based biopharmaceutical company founded in 1992 and publicly traded since 1996. The company specializes in developing and commercializing treatments for neurological, endocrine, and psychiatric disorders. Originally focused on research and development, Neurocrine has evolved into a commercial-stage company with multiple marketed products and a robust pipeline of investigational therapies. The company has established itself as a leader in movement disorders and rare diseases, with its flagship product INGREZZA becoming a blockbuster treatment for tardive dyskinesia.
Similar companies
Latest newsMore news →
Neurocrine Biosciences' IND for NBI-1117567 Phase 2 trial in Alzheimer's cognitive impairment was accepted by the US FDA, triggering a $10 million milestone payment to Nexera Pharma.9d agoAllworth Financial LP acquired a new position in Neurocrine Biosciences, Inc., purchasing 14,853 shares valued at approximately $2.50 million, as disclosed in a recent SEC filing.14d ago